tbuckley/cabot-search huggingface dataset:
Abstract 400: ERBB2 Inhibition Leads to Cardiac Dysfunction
Authors: Manveen K Gupta, Sathyamangla V Naga Prasad
Journal: Circulation Research (2018)

Growth factor ERBB2 inhibition is a reliable treatment for patients diagnosed with breast cancer but is known to cause cardiotoxicity, resulting in dysfunction and dilation. In our studies, we have taken a unique approach with the premise that ERBB2 inhibitors like trastuzumab or pertuzumab binding to ERBB2 may lead to a conformation that could engage/activate non-canonical signals while inhibiting classical pathways. Such non-canonical activation of signals by inhibitor may be beneficial for treating cancer, while the same pathways could be detrimental in the cardiomyocytes. Our data is further suppored by the microRNA-7 Transgenic mice developed in our lab, which downregulates ERBB2 leading to cardiac dysfunction as seen by echocardiography. These studies will lay the foundation for developing strategies that could specifically block the deleterious effect of ERBB2 inhibitors on the heart. Moreover, administration of AG825 in mice for two weeks results in significant cardiac dysfunction and dilation compared to AG1875 or vehicle controls, conferring the idea that inhibition of ERBB2 and not EGFR that mediates deleterious remodeling. Furthermore, mitochondria morphology was also affected upon ERBB2 inhibition as seen in our microRNA-7 transgenic mice hearts as well as AG825 (ERBB2 inhibtor) treated mice in the electrom micrographs. We will also discuss the proteomics analysis in the ERBB2 inhibitor treated hearts, microRNA-7 Transgenic mice hearts, ERBB2 transgenic mice hearts as compared to the C57/BL6 wildtype hearts. Our studies therefore aims to target these non-canonical signals in the heart with an idea to insulate the heart from the deleterious effects of chemotherapy.
C-REACTIVE PROTEIN LEVELS MODULATE LIPOPROTEIN(A)-ASSOCIATED CARDIOVASCULAR RISK IN OPTIMALLY-TREATED PATIENTS WITH HIGH-RISK VASCULAR DISEASE
Authors: Rishi Puri, Steven Nissen, Benoit Arsenault, Julie St. John, Jeffrey Riesmeyer, Giacomo Ruotolo, Leslie Cho, Venu Menon, A. Lincoff, Stephen Nicholls
Journal: Journal of the American College of Cardiology (2019)
IMPACT OF GENDER AND RACE ON OUTCOMES AFTER COMPLEX PERCUTANEOUS CORONARY INTERVENTION WITH THE PLATINUM-CHROMIUM EVEROLIMUS-ELUTING STENT: A POOLED ANALYSIS OF THE PLATINUM DIVERSITY AND PROMUS ELEMENT PLUS POST-APPROVAL STUDIES
Authors: Sherif Elsayed, Wayne Batchelor, Bimmer Claessen, Paul Guedeney, David Kandzari, Melissa Aquino, Scott Davis, Luis Tami, John Wang, Islam Othman, Osvaldo Gigliotti, Amir Haghighat, Sarabjeet Singh, Mario Lopez, Gregory Giugliano, Phillip Horwitz, Dominic Allocco, Ian Meredith, Paul Underwood, Roxana Mehran
Journal: Journal of the American College of Cardiology (2019)
RESISTIN AGGRAVATES ATHEROSCLEROSIS IN APOE-/- MICE AND IS ELEVATED IN HUMAN ATHEROSCLEROTIC LESIONS
Authors: Xinjiang Cai, Rihab Bouchareb, Soojeong Kang, Yassine Sassi, Shihong Zhang, K-Raman Purushothaman, Lahouria Hadri, Roger Hajjar, Djamel Lebeche
Journal: Journal of the American College of Cardiology (2019)
Identification of Syndecan-1 As a Key Dependency of Myeloid Leukemia Growth and Dissemination
Authors: Kyle Spinler, Tannishtha Reya, Jeevisha Bajaj, Takahiro Ito, Bryan Zimdahl, Armin Ahmadi, Claire Koechlein, Nikki Lytle, Hyog Young Kwon, Ferdous Anower-E-Khuda, Marcie Kritzik, Jan Karlseder, Pyong Woo Park, Jeffrey Esko
Journal: Blood (2018)
MAJOR BLEEDING IN PATIENTS WITH EMBOLIC STROKE OF UNDETERMINED SOURCE TREATED WITH DABIGATRAN VERSUS ACETYLSALICYLIC ACID (RE-SPECT ESUS TRIAL)
Authors: Christopher B. Granger, Hans-Christoph Diener, Ralph Sacco, J. Easton, Lisa Cronin, Mandy Fräßdorf, Claudia Grauer, Martina Brueckmann
Journal: Journal of the American College of Cardiology (2019)
MITRACLIP PLUS OPTIMAL MEDICAL THERAPY VERSUS OPTIMAL MEDICAL THERAPY ALONE FOR FUNCTIONAL MITRAL REGURGITATION: A META-ANALYSIS
Authors: Sunny Goel, Ravi Teja, Karan Wats, Elina Zakin, Srilekha Chava, Sergey Ayzenberg, Bilal Malik, Robert Frankel, Jacob Shani, Umesh Gidwani
Journal: Journal of the American College of Cardiology (2019)
A CASE OF INTERMITTENT PRE-EXCITATION AND RAPID AV CONDUCTION: IS IT TIME TO ABLATE ALL PATHWAYS?
Authors: Ariel Vinas, Dhanunjaya Lakkireddy, Manoj Panday, Ritvik Illindala, Jayasree Pillarisetti, Debanshu Roy
Journal: Journal of the American College of Cardiology (2019)
THE HIGH PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN A POPULATION OF ASCVD PATIENTS WITH LDL-C ABOVE TARGET: AN ANALYSIS FROM THE REACT REGISTRY
Authors: Milan Gupta, Magdaline Zawadka, Sumaia Aljenedil, Mahesh Kajil, David Bewick, Daniel Gaudet, Robert Hegele, Eva Lonn, Daniel Ngui, Latifah Alothman, Isabelle Ruel, Narendra Singh, Jacques Genest
Journal: Journal of the American College of Cardiology (2019)
Abstract P4-09-05: Withdrawn
Authors: L Veron, A Gelot, G Gusto, P Arveux, S Delaloge, M-C Boutron-Ruault
Journal: Cancer Research (2019)

Abstract This abstract was withdrawn by the authors. Citation Format: Veron L, Gelot A, Gusto G, Arveux P, Delaloge S, Boutron-Ruault M-C. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-09-05.
A PROSPECTIVE ANALYSIS OF CONTRAST PRESERVATION USING ULTRA-LOW CONTRAST DELIVERY TECHNIQUE VERSUS AUTOMATED CONTRAST INJECTOR SYSTEM IN CORONARY PROCEDURES
Authors: Adam T. Stys, Maheedhar Gedela, Udit Bhatnagar, Jeffrey Wilson, Natalia Stys, Terezia Petraskova, Alex Heard, Ben Staum, Valerie Bares, Marian Petrasko, Tadeusz Malinski, Tomasz Stys
Journal: Journal of the American College of Cardiology (2019)
Abstract ES5-3: Late recurrence in ER-positive breast cancer
Authors: J Gralow
Journal: Cancer Research (2019)

Abstract The risk of recurrence in early stage, ER-positive breast cancer patients persists for 15-20+ years after diagnosis, and never declines to zero. Rates of late recurrence can be reduced by extending tamoxifen therapy beyond 5 years, with additional tamoxifen or a switch to an aromatase inhibitor. The benefits of extending aromatase inhibitors beyond 5 years remains unclear. The benefit of extended adjuvant endocrine therapy for the average early stage breast cancer patient is small. Extended therapy can be associated with serious increased risks, including thromboembolic events and endometrial cancer with tamoxifen, and fractures and possibly cardiovascular events with aromatase inhibitors. Quality of life can also be impacted, including vasomotor symptoms, sexual dysfunction, and arthralgias. Determining which patients have high residual risk of recurrence beyond 5 years, and importantly whether additional therapy is likely to mitigate that risk, has been the subject of considerable recent research. Tumor size, nodal status and grade of the primary tumor at the time of diagnosis have been shown to be associated with risk of late recurrence in ER-positive breast cancer. Several multi-parameter molecular biomarker assays performed on the primary tumor are able to separate patients into groups at low and high risk for recurrence beyond 5 years when using retrospective data sets. To date, no specific assay has been felt to have high enough level evidence to recommend inclusion in treatment guidelines or use in decision-making regarding continuing, stopping or switching endocrine therapy. Recent studies have evaluated whether there are better determinants of late risk of recurrence, beyond the biology of the primary tumor, that can be performed years after the original diagnosis. Assays that may predict the presence of dormant tumor cells and late relapse include Circulating Tumor Calls (CTCs), Disseminated Tumor Cells (DTCs) in the bone marrow, and circulating tumor DNA, proteins or metabolites. While early data is promising, further research is needed before incorporating into clinical decision-making. Identifying a biomarker to determine patients most likely to benefit from longer duration endocrine therapy, or additional therapeutic approaches, could help in reducing late relapse as well as minimizing the risk of side effects and overtreatment. Citation Format: Gralow J. Late recurrence in ER-positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr ES5-3.
ISCHEMIC HEART DISEASE AND GENETIC POLYMORPHISMS IN THE CROSS - TALK BETWEEN MYOCARDIAL METABOLISM AND CORONARY FLOW: AN UPDATE
Authors: Mariateresa Pucci, Paolo Severino, Lucrezia Netti, Andrea D'Amato, Fabio Infusino, Simone Calcagno, Sara Cimino, Raffaele Palmirotta, Viviana Maestrini, Massimo Mancone
Journal: Journal of the American College of Cardiology (2019)
PERIPARTUM CARDIOMYOPATHY IN POSTPARTUM PERIOD IS ASSOCIATED WITH WORST OUTCOMES COMPARED TO ANTEPARTUM PERIOD: A PROPENSITY MATCHED ANALYSIS
Authors: Byomesh Tripathi, Purnima Sharma, Varunsiri Atti, Yash Jobanputra, Varun Kumar, Nilay Patel, Shilpkumar Arora, Sopan Lahewala, Abhishek Deshmukh, Alexander Egbe, Radha Gopalan
Journal: Journal of the American College of Cardiology (2019)
ASSOCIATION OF ATRIAL FIBRILLATION AND OUTCOMES IN OLDER PATIENTS WITH HEART FAILURE WITH PRESERVED AND REDUCED EJECTION FRACTION (HFPEF AND HFREF)
Authors: Apostolos Tsimploulis, Charles Faselis, Ioannis Kanonidis, Eric Rashba, Steven Singh, Prakash Deedwania, Gurusher Panjrath, Richard Allman, Gregg Fonarow, Ali Ahmed
Journal: Journal of the American College of Cardiology (2019)
HEART FAILURE AS A CONFOUNDER OF CHRONIC LUNG DISEASE IN PATIENTS WITH SEVERE AORTIC STENOSIS UNDERGOING TAVR
Authors: Jesus Pino, Varun Shah, Fergie Ramos Tuarez, Edwin Grajeda, Kai Chen, Samineh Sehatbakhsh, Swethika Sundaravel, Lovitz Lawrence, Mark Rothenberg, Roberto Cubeddu, Marcos Nores, Robert Chait
Journal: Journal of the American College of Cardiology (2019)
Abstract 440: The Cardiomyocyte Diastolic Stiffness and Contractility are Inversely Related to the Size of Titin: A Cellular Work Loop Study of Single Intact Cardiomyocytes
Authors: Mei Methawasin, Joshua Strom, Michiel Helmes, Henk Granzier
Journal: Circulation Research (2018)

Studying cardiac titin under physiological conditions can be at the level of the left ventricular (LV) chamber and the multicellular muscle level. However, those preparations are influenced by neurohormonal reflex, preload-afterload status and extracellular matrix. In this study, cellular work loop force measurement of the single intact cardiomyocyte was conducted under physiological conditions. Intact cell experiments were performed at 37°C under field-stimulation at 2 Hz frequency. The cell was attached to the force transducer and the piezo length controller which modulates the cell length by the feedback control system based on developed force. The force length relation (cellular work loop) of the single cell was generated. The end diastolic force length relation (EDFLR), the end systolic force length relation (ESFLR) and the preload recruitable stroke work (PRSW) were obtained. The Ttn ΔIAjxn -/- ( IA -/- ) mice, in which the I-band/A-band region of titin’s spring has been deleted were studied in comparison to α-MHC-Cre ; cRbm20 ΔRRM +/- ( cRbm20 +/- ) mice which are deficient in titin splicing and express large titin isoforms in the heart. The cellular diastolic stiffness (slope of EDFLR) was increased in IA -/- and was reduced in cRbm20 +/- (151.3, 104.0 and 91.5 μN/mm 2 in IA -/- , WT and cRbm20 +/- respectively). The contractility (slopes of ESFLR and PRSW) were 233.5 and 1215.6 uN/mm 2 in WT, and were increased in IA -/- (371.2 and 2076 μN/mm 2 ) but attenuated in cRbm20 +/- (202.9 and 907.7 μN/mm 2 ). Cellular work loop studies were also conducted in intact cells isolated from the mice that underwent transverse aortic constriction (TAC) surgery with deoxycorticosterone acetate (DOCA) implantation. TAC DOCA mice developed diastolic dysfunction at the LV chamber level. The result showed that the cells from TAC DOCA hearts had increased slopes of EDFLR, ESFLR and PRSW ( 157.9, 378.9 and 1699.0 μN/mm 2 ) compared to the cells from sham mice (98.6, 230.3, and 1203.9 μN/mm 2 ). Conclusions: Cellular work loops recapitulated the cardiac physiology at the LV chamber level. The result showed that the cellular diastolic stiffness and contractility were inversely related to the size of titin and that titin stiffness plays an important roles in both diastolic and systolic function.
Nucleotide Metabolism in Cardiac Activity
Authors: PHILIP A. KHAIRALLAH, W. F. H. M. MOMMAERTS
Journal: Circulation Research (1953)

Relaxed mammalian hearts contain ATP as the predominant nucleotide, sometimes accompanied by smaller amounts of ADP, presumably formed during manipulation. In systole, one-tenth of the nucleotide is changed into a new compound, nucleotide H.
OPTIMIZING THE DURATION OF MONITORING WITH THE DIAGNOSTIC YIELD FOR BRADYARRHYTHMIAS USING A NEXT GENERATION, FULL-DISCLOSURE MOBILE CARDIAC TELEMETRY DEVICE
Authors: Marek Jacek Dziubinski, Sanjeev Bhavnani, Michal Swiecak, Elzbieta Gajewska-Dendek, Olga Witkowska
Journal: Journal of the American College of Cardiology (2019)
Health organisations are slow to tackle gender inequality in workforce, report finds
Authors: Adrian O’Dowd
Journal: BMJ (2019)

Many health organisations around the world are making slow progress in tackling already identified longstanding problems of gender pay gaps and sexual harassment, a report has concluded.

The report,1 published on 7 March by Global Health 50/50, an independent initiative seeking to promote action and accountability for gender, analyses the policies and practices of 198 global health organisations covering an estimated 4.5 million employees. It is the second such annual report.

It shows that most organisations that are active in global health are failing to deliver on sexual harassment policies, gender pay gap reporting, and gender parity in leadership positions.

Data were gathered from October 2018 to February 2019 from a review of publicly available information on …
Abstract 450: Global Phosphopeptide Analyses Identifies a Profile that Distinguishes Advanced Heart Failure Patients Capable of Cardiac Recovery Following LVAD Unloading
Authors: Christopher Tracy, Aman Makaju, Sutip Navankasattusas, Lauren McCreath, Nikolaos Diakos, Craig Selzman, Stavros Drakos, Sarah Franklin
Journal: Circulation Research (2018)

The classical view of the human heart characterizes it as an organ with limited ability to recover and restore itself. Consequently, left ventricular assist devices (LVAD), which provide mechanical circulatory support and profound ventricular unloading, have been used as both a destination therapy as well as a bridge to transplantation in heart failure patients. However, evidence from many prospective studies indicates that a subset of patients with LVAD implants can significantly improve the structure and function of their heart (i.e. “responders”) and undergo LVAD explantation. This intriguing phenomenon provides great promise for heart failure patients, although the underlying mechanisms driving this recovery are largely unknown. To identify global changes in signaling pathways operative in the normal and failing human heart and to distinguish patients who respond to LVAD therapy from non-responders we performed phosphopeptide profiling and label-free quantitation of 38 patients. Our analysis utilized cardiac tissue from 10 donor controls, 6 recovered heart failure patients (responder), and 22 patients that did not respond to LVAD therapy (non-responders). Phosphopeptide enrichment and mass spectrometry-based analyses identified 15,816 unique phosphopeptides, 2,017 of which were shared between all samples. Label-free quantitation and bioinformatic analysis further classified 288 peptides [≥ 2 fold change (p&lt;0.01)] within this dataset that distinguish control tissue from those in heart failure. Most intriguing however, was our assessment of the phosphopeptide profile of heart failure patients at the time of LVAD implantation which, using a signature of 67 peptides [≥ 2 fold change (p&lt;0.01)], allowed complete separation of responder and non-responder samples via statistical analysis. Thus, this panel of 67 phosphopeptides enabled us to determine which patients would experience cardiac recovery following ventricular unloading prior to LVAD implantation. Overall this study characterizes unique changes in phosphoproteins and signaling pathways between the normal and failing human heart and specifies those which define hearts capable of cardiac recovery which may guide strategies to improving current heart failure therapies.
Abstract 346: A Standard Flow Cytometry Protocol for Assessing Human Pluripotent Stem Cell-derived Cardiomyocyte Identity by Troponin Positivity
Authors: Matthew Waas, Ranjuna Weerasekera, Erin M Kropp, Marisol Romero, Ellen Poon, Kenneth R Boheler, Paul W Burridge, Rebekah L Gundry
Journal: Circulation Research (2018)

Directed differentiation of human pluripotent stem cells (hPSC) into cardiomyocytes (hPSC-CM) offers an inexhaustible supply of cells for basic science research and translational applications. However, despite significant advancements in defining the factors most critical for differentiation, the resulting cultures remain a heterogeneous mixture of cells. Ultimately, as heterogeneity can pose challenges to interpreting functional data, the ability to accurately and precisely assess cell identity in differentiation cultures is paramount to well-defined and reproducible studies. To date, a standardized flow cytometry protocol that is broadly accepted among laboratories has not been established for assessing cell type heterogeneity within hPSC-CM cultures, posing challenges to evaluating outcomes generated among laboratories and studies. A survey of studies published over the past seven years (1/2010-10/2017) reveals the wide range of antibodies and experimental conditions reported for flow cytometry-based assessment of hPSC-CM. Although our literature survey revealed that a preponderance of studies relied on TNNT2 as a marker of cardiomyocyte identity, TNNI3 is more specific to cardiomyocytes than TNNT2 throughout development. We applied targeted mass spectrometry to confirm the presence of TNNI3 in our hPSC-CM. We then investigated five commercially available anti-TNNI3 and three sample preparation techniques for use in the assessment of heterogeneity of hPSC-CM cultures by flow cytometry. Results demonstrate two of the five anti-TNNI3 clones appear suitable for marking hPSC-CM and reveal differential susceptibility of antibody clones to sample preparation conditions. To further test the rigor and utility of our flow cytometry protocol, it was shared with two collaborating laboratories and applied to heterogeneous mixtures of positive and negative cell types. Results from these two laboratories demonstrate the protocol successfully distinguishes positive and negative cell types similarly, despite using different cell lines and differentiation protocols. We propose a workflow for establishing the fit-for-purpose use of antibodies and a standard protocol for assessing hPSC-CM identity by troponin positivity.
IL-6R blockade attenuates experimental allergic asthma associated with activation of the IL-6 trans-signalling pathway
Authors: M. A. Ullah, J. Revez, Z. Loh, J. Simpson, Zhang, L. Bain, A. Varelias, S. Rose-John, A. Blumenthal, M. Smyth, G. Hill, M. Sukkar, M. A. Ferreira, S. Phipps
Journal: Allergy (2015)
COMPARISON OF STANDARD-DOSE AND DOUBLE-DOSE DIRECT ORAL ANTI COAGULANTS (DOACS) FOR ACUTE PULMONARY EMBOLISM-THROMBUS QUANTITATIVE ANALYSIS
Authors: Katsushi Amemiya, Nobutaka Ikeda, Shuji Kubota, Naohiko Nemoto, Raisuke Iijima, Hidehiko Hara, Hitoshi Anzai, Yukio Hiroi, Masato Nakamura
Journal: Journal of the American College of Cardiology (2019)
Former NHS England director pleads guilty to voyeurism
Authors: Clare Dyer
Journal: BMJ (2019)

Jonathan Fielden, former deputy medical director of NHS England, has pleaded guilty to one count of voyeurism at Luton Crown Court.

Fielden, 55, who was also director of specialised commissioning services at NHS England, admitted to spying on an individual taking a shower through a hole in the loft of a private home. The admission relates to …
THE EFFECTS OF CD34+ CELL THERAPY ON FUNCTIONAL MITRAL REGURGITATION IN PATIENTS WITH NON-ISCHEMIC DILATED CARDIOMYOPATHY
Authors: Sabina Frljak, Gregor Zemljic, Gregor Poglajen, Andraz Cerar, Martina Jaklic, Francois Haddad, Bojan Vrtovec
Journal: Journal of the American College of Cardiology (2019)
PRELIMINARY RESULTS OF ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR EFFECT ON TEI INDEX AND LEFT VENTRICULAR MASS IN HEART FAILURE (ARTIM HF) TRIAL
Authors: Rajendra Kumar Gokhroo, Kumar Ashish, Kailash Chandra, Nandal Rajesh, Tarik Tasleem, Anushri Kaul
Journal: Journal of the American College of Cardiology (2019)
SABR in high-risk prostate cancer: Outcomes from two prospective clinical trials with and without elective nodal irradiation.
Authors: Yasir Alayed, Patrick Cheung, Danny Vesprini, Stanley K. Liu, William Chu, Hans T. Chung, Hima Bindu Musunuru, Melanie Davidson, Ananth Ravi, Ling Ho, Andrea Deabreu, Laura D'alimonte, Zeeba Bhounr, Liying Zhang, Kristina Commisso, Andrew Loblaw
Journal: Journal of Clinical Oncology (2019)

3 Background: There is limited data on SABR in high-risk prostate cancer (PCa) especially regarding the role of elective nodal irradiation (ENI). This study compares two prospective phase II trials using SABR in high-risk prostate cancer, with and without ENI. Methods: Both trials enrolled patients with high-risk PCa only. Trial1 (pHART8) patients received 40Gy/5 to the prostate and 30Gy/5 to the seminal vesicles. Trial2 (SATURN) patients received 40Gy/5 to the prostate and 25Gy/5 to the pelvis and seminal vesicles. CTCAE and RTOG toxicities were collected. Biochemical failure (BF) was defined as nadir+2 and 4-year PSA response rate (4yPSARR) was &lt; 0.4 ng/ml. Results: 60 patients were included (pHART8, n=30; SATURN, n=30). Median follow-up was 5.6y and 4.0y. Median nPSA was 0.02ng/ml for both. Six patients had BF, all from pHART8; four were managed with ADT and two are being observed. The BF rate was 14.6% at 5y in pHART8 and 0% in SATURN. All six biochemical failures were associated with a PSA of ≥ 0.4 ng/ml at 4y. 63% of patients in pHART8 and 93% in SATURN had a 4yPSARR. BF probability at 5y was 0% for those achieving a 4yPSARR, and 35.1% if not (p = p &lt; 0.0001). Two patients died in pHART8, one from metastatic disease. One patient in SATURN died from other causes. No other patients developed metastatic disease, and one patient in pHART8 had CRPC. OS at 5y was 93.2% and 96.7% (p=0.86). There was significantly worse late GI and sexual toxicity in pHART8, but no difference in late GU toxicity between the two trials. Conclusions: SABR in high-risk prostate cancer yields biochemical control rates that are comparable to other radiotherapy modalities. ENI using SABR is feasible and led to a significant improvement in biochemical control as well as in 4yPSARR which proved to be a predictor of biochemical control, without an increase in late GI or GU toxicity. Longer follow-up would provide a better assessment of biochemical control. Clinical trial information: NCT01505075 and NCT01953055.
UTAH CARDIAC RECOVERY SCORE EFFECTIVELY PREDICTS MYOCARDIAL RECOVERY IN PATIENTS SUPPORTED WITH DURABLE LEFT VENTRICULAR ASSIST DEVICES
Authors: Iosif Taleb, Benjamin Horne, Michael Yaoyao Yin, Anna Catino, Omar Wever-Pinzon, Michael Bonios, William Caine, Antigoni Koliopoulou, Rami Alharethi, Abdallah Kfoury, Line Kemeyou, James Fang, Josef Stehlik, Craig Selzman, Stavros Drakos
Journal: Journal of the American College of Cardiology (2019)